ResearchersDrug Pipelines

Drug Pipelines

Phase I
VILLARIS Therapeutics

Company is developing a novel humanized anti IL-15R antibody to target depletion of resident memory T-cells. It hopes to launch early human trials in 2021/2.
VALLAURIX / Clinuvel Pharmaceuticals

Parvysmelanotide (VLRX001) contains a specific peptide sequence, designed to make it less susceptible to degradation than physiologic (natural) alpha-melanocyte stimulating hormone (α-MSH).
Bioniz Therapeutics / Almirall

BNZ-1 for an immuno-dermatology franchise in vitiligo, cutaneous T-cell Lymphoma and alopecia areata. The lead product candidate has completed Phase 1 SAD and MAD clinical trials in healthy volunteers and is currently in Phase1/2a clinical development in CTCL.
BOSTON Pharmaceuticals

Company in-licensed topical compound BOS-475 (formerly GSK3183475) to treat vitiligo and psoriasis. This Phase I-ready compound is a small molecule inhibitor of Bromodomain and Extra-Terminal. It reduces the expression of pro-inflammatory mediators, such as IL-17 and Th1-associated chemokines.
AXIM Biotechnologies

Drug candidate AX-1602. Company filed patent application for a method to treat vitiligo with a topical composition containing cannabidiol and cannabigerol. Specific details not yet available.
ARRIEN Pharmaceuticals

Company develops an orally available JAK3 inhibitor ARN-4079, which targets unique Cys909 residue at the gatekeeper position. The company plans to file for IND to treat vitiligo and other skin diseases. It is currently seeking partnerships that will help it fulfill IND-enabling studies and Phase I clinical trials.
ACHE Laboratorios Farmaceuticos

The Brazilian regulatory agency - ANVISA - has requested back in 2016 the cancellation of the Phase 3 study for drug candidate ACH24 study for conducting a Phase 1 study first. Specific details not yet available.
TEMPRIAN Therapeutics

Company is actively seeking partnerships to advance TT-01 development, a DNA-based therapy for vitiligo. It uses a modified HSP70i developed by Prof. Caroline Le Poole at Northwestern and Loyola Universities.
RHEOS Medicines

Company is focused on suppressing T-cell effector responses for lupus and vitiligo. It aims to modulate metabolic pathways in immune cells — mainly CD4 and CD8 T cell subtypes.
PALATIN Technologies

Company filed patent application for melanocortin receptor-1 peptides (MC-1) back in 2013. Specific details not yet available.
LSI (Life Science Investments)

Company is pre-clinical trials for VITILSI. This is the only plant-based, cosmeceutical formulation in the pipeline with antioxidant, anti-inflammatory and immunomodulatory properties, combined with melanogenesis-inducing properties of Coleus forskohlii root and Cassia alata leaves extract.

Drug candidate CCP-070 is in the preclinical stage for a ‘rare dermatologic condition’. The company in-licensed these tri- and tetra-peptide melanotropic analog series from Prof. Abdel-Malek at the University of Cincinnati. Promising peptide structures are small enough to achieve dermal penetration after topical application.
Phase II

PF-06651600, a selective JAK1 inhibitor, and PF-06700841, a tyrosine kinase 2(TYK2)/JAK1 inhibitor, are in Phase 2b/3 program to evaluate the efficacy and safety profile of in subjects with active non-segmental vitiligo.
Arcutis Biotherapeutics

SHR0302, the active ingredient in ARQ-252, a potent and highly selective inhibitor of janus kinase type 1 (JAK1). Arcutis believes this compound has a promising treatment potential without hematopoietic adverse effects typically associated with JAK2 inhibition. Arcutis anticipates initiating a Phase 2a study in the second half of 2020.
DERMAVANT / Roviant Sciences

Company is advancing a pipeline of treatment candidates for vitiligo and other conditions with topical JAK/Syk inhibitor Cerdulatinib (also named DMVT-504 or RVT-502, in-licensed from Portola Pharmaceuticals for topical indications)
Phase III

A well-known Ruxolitinib is a potent inhibitor of JAK1/JAK2 with good safety profile. It works on vitiligo by suppressing the overactive TH1 arm of the body's immune system, which is responsible for the depigmentation. With all four doses of topical ruxolitinib most patients have reached over 50%, while one-third of patients had complete facial repigmentation after 24 weeks. Clinical Trial 1 and Clinical Trial 2